<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03903016</url>
  </required_header>
  <id_info>
    <org_study_id>BEQ15846</org_study_id>
    <secondary_id>2018-003131-30</secondary_id>
    <secondary_id>U1111-1207-8959</secondary_id>
    <nct_id>NCT03903016</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes</brief_title>
  <official_title>A Randomized, Double-blind, Single-dose, 2-treatment, 2-period, 2-sequence Crossover Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate bioequivalence between insulin lispro given as SAR342434, 200 Units/ml test
      formulation (T) and insulin lispro 100 Units/ml reference formulation (R) after a single
      subcutaneous (SC) dose

      Secondary Objectives:

        -  To assess the pharmacodynamic profiles and further pharmacokinetic characteristics of
           the test formulation (T) in comparison to the reference formulation (R) after a single
           SC dose

        -  To assess the safety and tolerability of the test and the reference formulation of
           insulin lispro
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant is approximately 62 days including a screening period up to 28
      days before first dose, 2 periods of 2 days, a wash out period of 5 to 18 days (preferred7
      days) and an end of study visit 7 to 14 days after the last dose
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Actual">August 19, 2019</completion_date>
  <primary_completion_date type="Actual">August 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of pharmacokinetc (PK) parameter:INS-Cmax</measure>
    <time_frame>10 hours</time_frame>
    <description>Maximum Insulin (INS) concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of PK parameter :INS-AUClast -</measure>
    <time_frame>10 hours</time_frame>
    <description>Area under INS concentration time curve from 0 to last measurable concentration -</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter:INS-AUC</measure>
    <time_frame>10 hours</time_frame>
    <description>Area under INS concentration time curve from 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter:INS-tmax</measure>
    <time_frame>10 hours</time_frame>
    <description>Time to reach INS-Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter:INS-t1/2z</measure>
    <time_frame>10 hours</time_frame>
    <description>INS terminal half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacodynamic (PD) parameter:GIR-AUC0-8</measure>
    <time_frame>8 hours</time_frame>
    <description>Area under the Glucose Infusion Rate (GIR) time curve from 0 to 8 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter:GIR-max</measure>
    <time_frame>8 hours</time_frame>
    <description>Maximum smoothed GIR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PD parameter:GIR-tmax</measure>
    <time_frame>8 hours</time_frame>
    <description>Time to reach GIR-max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of blood glucose control</measure>
    <time_frame>8 hours</time_frame>
    <description>Duration of blood glucose control at or below 105 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to Day 62</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Test (T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Lispro (SAR342434), 200 Units/ml, single dose on day 1 of each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference (R)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Lispro Sanofi® ,100 Units/ml, single dose on day 1 of each period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro SAR342434</intervention_name>
    <description>Pharmaceutical form:solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>Test (T)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro SAR342434</intervention_name>
    <description>Pharmaceutical form:solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>Reference (R)</arm_group_label>
    <other_name>Insulin lispro Sanofi®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Male or female patients, between 18 and 64 years of age, inclusive, with diabetes
             mellitus type 1 for more than one year

          -  Total insulin dose of &lt;1.0 U/kg/day

          -  Fasting serum C-peptide &lt;0.30 nmol/L at screening

          -  Glycohemoglobin (HbA1c) ≤75 mmol/mol (≤9%) at screening

          -  Stable insulin regimen for at least 2 months prior to study (day of insulin regimen
             switch, with respect to safety of the patient and scientific integrity of the study).

          -  Patients with anti-insulin antibody titer at screening ≤ 30.0 kU/L

          -  Body weight between 50.0 kg and 100.0 kg, inclusive, il male , and between 40.0 and
             90.0 kg, inclusive, if female, Body Mass Index between 18 and 30.0 kg/m², inclusive

        Exclusion criteria:

          -  Any history or presence of clinically relevant cardiovascular, pulmonary,
             gastrointestinal, hepatic, renal, metabolic, hematological, neurological,
             osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or
             infectious disease, or signs of acute illness or any history or presence of HIT-type
             II (heparin induced thrombocytopenia Type II)

          -  More than 1 episode of severe hypoglycemia resulting in coma/seizures or requiring
             assistance of another person, and/or hospitalization for diabetic ketoacidosis in the
             last 6 months before screening visit.

          -  Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting
             only, more than twice a month).

          -  Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or
             asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20
             mmHg within 3 minutes when changing from supine to standing position.

          -  Presence or history of drug hypersensitivity, or allergic disease diagnosed and
             treated by a physician.

          -  Likelihood of requiring treatment during the study period with drugs not permitted by
             the clinical study protocol

          -  If female, pregnancy (defined as positive β-HCG blood test), breast-feeding

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 2760001</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

